Camurus AB (publ) (FRA:7CA)
Germany · Delayed Price · Currency is EUR | Market Cap | 3.31B -11.0% |
| Revenue (ttm) | 204.71M +0.0% |
| Net Income | 61.25M -5.6% |
| EPS | 1.02 -6.2% |
| Shares Out | n/a |
| PE Ratio | 54.06 |
| Forward PE | 33.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 55.65 |
| Previous Close | 55.20 |
| Day's Range | 54.25 - 55.65 |
| 52-Week Range | 40.60 - 67.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and is under phase III clinical trials to treat gastroenteropancreatic neu... [Read more]
Financial Performance
In 2025, Camurus AB's revenue was 2.27 billion, an increase of 21.30% compared to the previous year's 1.87 billion. Earnings were 735.57 million, an increase of 71.70%.
Financial numbers in SEK Financial StatementsNews
Camurus' CAM2029 NDA Back Under FDA Review; PDUFA Set For Dec
(RTTNews) - Camurus AB (publ) (CAMX.ST), a biopharmaceutical company, announced on Friday that the U.S. Food and Drug Administration has accepted the resubmitted New Drug Application for CAM2029 for r...
Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA
PDUFA target action date set to 18 December 2026 LUND, Sweden, July 17, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has accepted for ...
Camurus AB Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue and profit growth, record product sales, and robust cash flow. Key products Buvidal and Brixadi delivered double-digit growth, while pipeline and commercial expansion remain top priorities. Regulatory and capacity risks are being actively managed.
Camurus AB Quarterly report: Q2 2026
Camurus AB has published its Q2 2026 quarterly earnings report on July 15, 2026.
Camurus AB Slides: Q2 2026
Camurus AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 15, 2026.
Camurus' hormone disorder drug expected to be approved in 2027 after fresh FDA setback
Wall Street has pushed to next year expectations for a U.S. approval for Camurus' drug to treat a rare hormonal condition after the health regulator's second refusal on Wednesday.
Camurus AB Slides: Company presentation
Camurus AB has posted slides in relation to its latest quarterly earnings report, which was published on June 5, 2026.
Camurus AB Transcript: Jefferies Global Healthcare Conference 2026
Strong commercial growth and pipeline progress are expected, with Buvidal targeting 100,000 patients by end-2027 and key milestones for BRIXADI and CAM2029 anticipated in 2026. Strategic partnerships and M&A remain central to expansion plans.
Camurus announces expansion of Lilly collaboration
LUND, Sweden, June 1, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the ...
Camurus AB Slides: Company presentation
Camurus AB has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Camurus AB Earnings Call Transcript: Q1 2026
Q1 2026 results showed sequential revenue growth and strong profitability, with robust in-market demand for key products and a solid cash position. Full-year guidance was reaffirmed, with major milestones ahead including FDA decisions and pivotal study readouts.
Camurus AB Quarterly report: Q1 2026
Camurus AB has published its Q1 2026 quarterly earnings report on May 12, 2026.
Camurus AB Slides: Q1 2026
Camurus AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
Camurus AB Slides: Company presentation
Camurus AB has posted slides in relation to its latest quarterly earnings report, which was published on April 13, 2026.
Camurus AB Slides: Company presentation
Camurus AB has posted slides in relation to its latest quarterly earnings report, which was published on March 6, 2026.
Camurus AB Earnings Call Transcript: Q4 2025
2025 saw strong revenue and profit growth, driven by Brixadi royalties and Buvidal expansion, despite FX headwinds and a UK distribution change. Regulatory milestones included Oczyesa approval and launch, while R&D advanced with positive CAM2056 results. 2026 guidance anticipates continued double-digit growth and increased investment in U.S. operations.
Camurus AB Quarterly report: Q4 2025
Camurus AB has published its Q4 2025 quarterly earnings report on February 12, 2026.
Camurus AB Slides: Q4 2025
Camurus AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.
Camurus AB Annual report: Q4 2025
Camurus AB has published its Q4 2025 annual report on February 12, 2026.
Camurus AB Slides: Company presentation
Camurus AB has posted slides in relation to its latest quarterly earnings report, which was published on January 12, 2026.
Camurus announces FDA acceptance of NDA resubmission for Oclaiz
Camurus (CAMRF) announced that the U.S. Food and Drug Administration has accepted for review the company’s resubmission of the New Drug Application for Oclaiz, octreotide extended-release injection, f...
Camurus AB Transcript: Jefferies London Healthcare Conference 2025
Strong clinical data for CAM2056 and expanding partnerships highlight growth in cardiometabolic and opioid use disorder markets. Regulatory progress for Octase and robust commercial uptake in key regions support a positive outlook, despite recent financial guidance adjustments.
Camurus AB Slides: Company presentation
Camurus AB has posted slides in relation to its latest quarterly earnings report, which was published on November 18, 2025.
Camurus reports positive topline results for CAM2056, semaglutide monthly depot
CAM2056 showed weight and A1c reductions comparable to or exceeding those seen for weekly semaglutide (Wegovy®) Results include a 9.3% weight reduction with CAM2056 vs. 5.2% with weekly semaglutide at...
Camurus AB Earnings Call Transcript: Q3 2025
Q3 2025 saw strong profitability, 18% revenue growth year-on-year, and robust cash flow, but full-year revenue guidance was lowered due to U.S. and U.K. headwinds. Product launches and pipeline progress continued, with Oczyesa launched in Germany and Brixadi gaining U.S. market share.